Katie Quinn

Get more out of your business.

Reach it with Microsoft Dynamics 365 Business Central.

October 24, 2017 Katie Quinn

Biosimilars Forum Applauds Food and Drug Administration on New Educational Program Promoting Safety and Effectiveness of Biosimilars

September 14, 2017 Katie Quinn

Biosimilars Forum Opposes Current CMS Rule That Would Adversely Affect Biosimilars Development in the U.S.; Submits Comments on Appropriate Biosimilar Reimbursement Policy

August 19, 2017 Katie Quinn

Biosimilars Forum Applauds President Trump for Signing the FDA Reauthorization Act

August 3, 2017 Katie Quinn

Biosimilars Forum Applauds Senate Passage of the FDA Reauthorization Act

July 19, 2017 Katie Quinn

Biosimilars Forum Makes Available Xcenda Study on Budgetary Impact of Biosimilars Coding

July 14, 2017 Katie Quinn

Biosimilars Forum Applauds CMS Decision to Revisit Biosimilars Coding Policy

May 12, 2017 Katie Quinn

Biosimilars Forum Applauds Senator Roberts, Reps. Barton, Eshoo for Leadership on Medicare Policy on Biosimilar Coding

May 11, 2017 Katie Quinn

Biosimilars Forum Statement Regarding Newly Released EMA Information Guide on Biosimilars For Healthcare Professionals

May 10, 2017 Katie Quinn

Biosimilars Forum Statement Regarding Confirmation of Dr. Scott Gottlieb as Commissioner of the Food and Drug Administration

May 3, 2017 Katie Quinn

Biosimilars Forum Submits Comments in Response to FDA’s Draft Guidance for Industry on Interchangeability for Biosimilar Products